Patents by Inventor Rudolf Hartmann
Rudolf Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793855Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: GrantFiled: January 14, 2019Date of Patent: October 24, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 10800816Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: November 16, 2017Date of Patent: October 13, 2020Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
-
Publication number: 20190134147Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: ApplicationFiled: January 14, 2019Publication date: May 9, 2019Applicants: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 10201586Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: GrantFiled: December 9, 2016Date of Patent: February 12, 2019Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 10124033Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: GrantFiled: August 19, 2016Date of Patent: November 13, 2018Assignees: BAXALTA INCORPORATED, BAXALTA GMBHInventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Publication number: 20180155399Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: November 16, 2017Publication date: June 7, 2018Applicants: Baxalta GmbH, Baxalta IncorporatedInventors: Michael DOCKAL, Rudolf HARTMANN, Friedrich SCHEIFLINGER, Frank OSTERKAMP, Thomas POLAKOWSKI, Ulrich REINEKE
-
Patent number: 9873720Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: December 29, 2014Date of Patent: January 23, 2018Assignees: Baxalta GmbH, Baxalta IncorporatedInventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
-
Publication number: 20170174727Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: December 29, 2014Publication date: June 22, 2017Applicants: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: MICHAEL DOCKAL, RUDOLF HARTMANN, FRIEDRICH SCHEIFLINGER, FRANK OSTERKAMP, THOMAS POLAKOWSKI, ULRICH REINEKE
-
Publication number: 20170157198Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, an identify a TFPI-binding compound.Type: ApplicationFiled: December 9, 2016Publication date: June 8, 2017Applicants: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Publication number: 20170035835Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: ApplicationFiled: August 19, 2016Publication date: February 9, 2017Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Patent number: 9556230Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: April 2, 2015Date of Patent: January 31, 2017Assignees: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 9447147Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: GrantFiled: February 27, 2015Date of Patent: September 20, 2016Assignees: BAXALTA GMBH, BAXALTA INCORPORATEDInventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Publication number: 20150246947Abstract: The invention provides peptides, including peptides that bind and, optionally, inhibit Protein S, and compositions thereof. The peptides may be used to, e.g., inhibit Protein S activity, enhance thrombin formation in a subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify Protein S, and identify a Protein S binding compound.Type: ApplicationFiled: February 27, 2015Publication date: September 3, 2015Inventors: Michael Dockal, Thomas Polakowski, Frank Osterkamp, Rudolf Hartmann, Matthias Paschke, Bettina Hartlieb, Friedrich Scheiflinger
-
Publication number: 20150232514Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: April 2, 2015Publication date: August 20, 2015Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 9018167Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: March 18, 2013Date of Patent: April 28, 2015Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Patent number: 8962563Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: January 31, 2013Date of Patent: February 24, 2015Assignees: Baxter International, Inc., Baxter Healthcare SAInventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
-
Publication number: 20130259863Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: March 18, 2013Publication date: October 3, 2013Inventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski
-
Publication number: 20130252896Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. Peptide complexes also are provided. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: ApplicationFiled: January 31, 2013Publication date: September 26, 2013Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger, Frank Osterkamp, Thomas Polakowski, Ulrich Reineke
-
Patent number: 8513386Abstract: The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors.Type: GrantFiled: April 28, 2011Date of Patent: August 20, 2013Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Michael Dockal, Rudolf Hartmann, Friedrich Scheiflinger
-
Patent number: 8450275Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.Type: GrantFiled: February 11, 2011Date of Patent: May 28, 2013Assignees: Baxter International Inc., Baxter Healthcare SAInventors: Michael Dockal, Rudolf Hartmann, Markus Fries, Friedrich Scheiflinger, Hartmut Ehrlich, Ulrich Reineke, Frank Osterkamp, Thomas Polakowski